New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?

Abstract

Aging is characterized by the loss of homeostasis that leads to changes in the biochemical composition of tissues, reduced ability to respond adaptively to environmental stimuli, and increased susceptibility and vulnerability to diseases including coronary artery diseases, carotid artery disease and brain vessel disease. Hypercholesterolemia is one of the primary risk factors for these pathologies, whose incidence is highly related to aging. Almost 25% of men and 42% of women older than 65 years have a serum total cholesterol level greater than 240 mg/dL. The mechanisms behind this age-related increase in plasma cholesterol are still incompletely understood, thus, the control of plasma cholesterol content in aged people is more challenging than in adults. In this review the different pharmacological approaches to reduce plasma cholesterol levels, particularly in aged people, will be discussed. In brief, current therapies are mostly based on the prescription of statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) that are pretty effective but that exert several side effects. More attention should be given to potential drug interactions, potential age-related changes in drug pharmacokinetics, adverse effects such as myopathy and competing risks when statins are prescribed to old patients. In combination or in alternative to statin therapy, other agents might be required to reduce low density lipoprotein (LDL) cholesterol levels. Among the available drugs, the most commonly prescribed are those addressed to reduce cholesterol absorption, to modulate lipoprotein lipase activity and bile acid sequestrants: even these pharmacological interventions are not exempt from side effects. The use of antioxidants or organoselenium compounds and the discovery of new proteins able to modulate exclusively LDL receptor recycling such as Proprotein convertase subtilisin kexin 9 and SEC24 offer new pharmacological approaches to selectively reduce the main causes of dyslipidemia.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved. Key words: Aging; Cholesterol; HypercholesterolemiaCore tip: The strategies used to reduce plasma cholesterol levels in elderly people are mainly addressed to the inhibition of the rate limiting enzyme of cholesterol biosynthetic pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), in order to increase low density lipoprotein (LDL) receptor membrane exposure and LDL clearance from the circulation. Indeed current therapies are mostly based on the prescription of statins (HMGR inhibitors) that are pretty effective but that exert side effects. More attention should be given to potential drug interactions, potential age-related changes in drug pharmacokinetics, adverse effects such as myopathy and competing risks when statins are prescribed to elderly. Thus, new therapeutic agents should be taken into account.Trapani L, Segatto M, Pallottini V. New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid

Cholesterol Metabolism Is Altered in Rett Syndrome: A Study on Plasma and Primary Cultured Fibroblasts Derived from Patients

“…To start, the attention was focused on HMGR, the rate and limiting enzyme of cholesterol biosynthetic pathway [19], [20].…”

“…Once ascertained the reliability of the experimental model of fibroblast culture and the prospective deregulations both in plasma cholesterol profile and in SRB1, the main proteins involved in the regulatory network of cholesterol metabolism were evaluated. To start, the attention was focused on HMGR, the rate and limiting enzyme of cholesterol biosynthetic pathway [19] , [20] .…”

Using Computational Drug-Gene Analysis to Identify Novel Therapeutic Candidates for Retinal Neuroprotection

“…Statins are HMG-CoA reductase inhibitors and another class of FDA-approved drugs currently used for lipid-lowering therapy but have also demonstrated neuroprotective effects through various mechanisms including anti-inflammation, apoptosis regulation, and antioxidation [ 69 ]. Cholesterol is required for neuronal processes that include neurite formation, myelination, and synapse activity, which means that the brain possesses an incredibly high cholesterol demand as it utilizes around 25% of the total body cholesterol despite only representing 2% of the total body weight [ 70 , 71 ]. In the retina, statins have long been theorized to treat neurodegenerative diseases such as AMD due to the role of cholesterol in drusen formation, a well-known feature of AMD.…”

Loss of Mevalonate/Cholesterol Homeostasis in the Brain: A Focus on Autism Spectrum Disorder and Rett Syndrome

“…A rise in LDLR expression was noted in RTT fibroblasts [75]. These changes suggest that low intracellular cholesterol content, as a consequence of HMGCR activity suppression in RTT fibroblasts, induces the classic feedback mechanism with activation of SREBP2 and the increase of its transcriptional targets such as LDLR (LDL receptor) and HMGCR [23,55,103,104,105,106,107]. Furthermore, LDLR increase is also promoted by the decrease in degradative events, as suggested by the fall in Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9, a protein involved in LDLR degradation) plasma levels in RTT individuals [75].…”